RxDoctor Payments DataLook up a doctor →

Keith Harris, MD

Dermatology · Cartersville, GANPI 1922090224

Payments from drug & device makers

$17,469in general payments, 2019–2025

Across 674 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AbbVie$3K
  • UCB, Inc.$1K
  • Lilly USA, LLC$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Johnson & Johnson$1K
  • plus $7K from 34 others

What the payments were for

  • Consulting fees$1,92011%
  • Food & beverage$14,86885%
  • Education$6814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,469 in reported general payments places this provider in the 80th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$395,876
Medicare patients
1,114
Services billed
7,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa19$400,616
Humira(Cf) PenAdalimumab25$340,954
OtezlaApremilast66$285,538
Dupixent PenDupilumab40$154,553
Taltz AutoinjectorIxekizumab12$80,813
Dupixent SyringeDupilumab23$80,529
Cimzia (2 Pack)Certolizumab Pegol11$74,759
Betamethasone Dipropionate214$6,490
Metronidazole81$5,570
Tacrolimus46$5,437
Ketoconazole326$5,089
Clobetasol Propionate143$4,982
Ammonium Lactate255$3,831
CiclopiroxCiclopirox Olamine127$3,337
Fluorouracil38$2,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$333$285,53866 claims
UCB, Inc.Cimzia (2 Pack)$1,184$74,75911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 345 dermatology providers in Georgia.

Other dermatology in Cartersville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →